文献速递外周动脉疾病

药物洗脱可吸收支架治疗股浅动脉病变的两年分析

The Drug-Eluting Resorbable Scaffold in the Superficial Femoral Artery: 2-year Analysis.
PubMed 文献 · Ann Vasc Surg · 2026-03-11

这项首次人体研究评估了紫杉醇洗脱可吸收支架治疗30例股浅动脉原发病变的安全性和性能。器械成功部署率100%,12个月二元再狭窄率4.35%,踝肱指数从术前0.58±0.17改善至0.83±0.17(P<0.0001)。2年内无手术或器械相关死亡和截肢,85.71%患者Rutherford-Becker分级较术前改善。

要点

  • 药物洗脱可吸收支架在股浅动脉原发病变中器械成功部署率100%
  • 12个月二元再狭窄率4.35%,踝肱指数显著改善
  • 2年内无手术或器械相关死亡和截肢,临床改善持续

核心结论

  • 该药物洗脱可吸收支架在2年内未发生手术或器械相关死亡和截肢,安全性得到证实。
  • 12个月双功超声显示持续通畅,再血管化发生率低,与之一致。
  • 2年时Rutherford-Becker临床分级改善比例仍较高。

研究设计与样本

  • 首次人体研究,评估药物洗脱可吸收支架治疗股浅动脉原发病变的安全性和性能。
  • 共纳入30例股浅动脉原发闭塞或狭窄患者。
  • 器械为紫杉醇洗脱聚(L-丙交酯-co-ε-己内酯)支架,采用专有3D多轴精密打印技术。

主要发现

  • 病变位于股浅动脉,平均病变长度37.76±17.45 mm。
  • 器械成功部署率100%。
  • 12个月时发生两例无关死亡,其余病例无截肢。
  • 12个月二元再狭窄率为4.35%。
  • 踝肱指数从术前0.58±0.17改善至12个月随访时0.83±0.17(P<0.0001)。

临床怎么用

  • 对于股浅动脉原发病变,可考虑使用该药物洗脱可吸收支架,其短期至中期安全性和临床改善较好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In-stent restenosis remains a challenge in superficial femoral artery (SFA) treatment, though a great efficacy has been shown in drug-eluting stents (DESs). The concept of "leave nothing behind" has further driven interest to bioresorbable vascular stents. Some drug-eluting resorbable scaffold (DRS) has shown promise in coronary artery and SFA. We brought a first in-human study of DRS for treatment of peripheral artery disease (PAD) involving the de novo lesions in SFA. METHODS: This DRS system is a device-drug combination consisting of a paclitaxel-eluting poly (L-lactide-co-ε-caprolactone) scaffold, using proprietary 3D multi-axis precision printing technology. Safety and performance were evaluated in 30 patients with de novo occlusion or stenosis in SFA. RESULTS: De novo lesions were located in SFA. Mean lesion length was 37.76 ± 17.45 mm. The study device was successfully deployed in 100% of cases. At 12 months, there were two unrelated deaths, and no amputations occurred in the rest cases. The binary restenosis rates were 4.35%. The ankle brachial index improved from preprocedural 0.58 ± 0.17 to 0.83 ± 0.17 at 12 months of follow-up (P < 0.0001). At 2 years, 85.71% of the patients improved in Rutherford-Becker compared to the score preprocedure. CONCLUSION: The safety of this DRS was demonstrated with no procedure or device-related deaths and amputations within 2 years. The low occurrence of revascularizations was consistent with duplex-ultrasonography showing sustained patency at 12 months. The percent of improvement in Rutherford-Becker clinical category was still high at 2 years.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Yang L, Che Y, Tang X, et al. The Drug-Eluting Resorbable Scaffold in the Superficial Femoral Artery: 2-year Analysis. Ann Vasc Surg. 2026. PMID: 41825509. doi:10.1016/j.avsg.2026.02.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。